A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

To be considered for this study, you would need to have been diagnosed with a specific type of diffuse large B-cell lymphoma (DLBCL) called germinal center B-cell (GCB) subtype. Doctors would confirm this from a biopsy you've already had. You also need to have active cancer that can be seen on a special scan called a PET scan, and you mustn't have had any prior treatment for your DLBCL.

There are also some health conditions that might prevent you from taking part. For example, if you have certain heart problems, ongoing nerve damage (peripheral neuropathy), or a history of specific types of lymphoma like primary mediastinal B-cell lymphoma. If you have HIV, hepatitis B, or hepatitis C, you might still be able to join if these conditions are well-controlled by your current medication.

Generally, participants need to be 18 years old or over. The study is open to both men and women. The researchers will thoroughly check your medical history to make sure the study is a safe and appropriate option for you.

If you join this study, you will receive one of two treatment combinations consisting of different medications, alongside the standard R-CHP therapy, over several cycles. This will involve regular visits to the clinic for treatments, medical check-ups, blood tests, and scans to monitor your health and how the treatment is working. You will be closely monitored for any side effects. The exact number of visits, tests, and total duration of your participation will be explained in detail by the study team, but it will involve ongoing assessments and follow-up to track your progress after treatment has finished.